About Abivax S.A.
https://www.abivax.comABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France.
CEO
Marc de Garidel
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 19
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Guggenheim
Buy
BTIG
Buy
Citizens
Market Outperform
JMP Securities
Market Outperform
Citizens Capital Markets
Market Outperform
LifeSci Capital
Outperform
Grade Summary
Showing Top 6 of 8
Price Target
Institutional Ownership
TCG CROSSOVER MANAGEMENT, LLC
Shares:7.11M
Value:$889.02M
UBS GROUP AG
Shares:4.46M
Value:$557.7M
DARWIN GLOBAL MANAGEMENT, LTD.
Shares:3.16M
Value:$395.59M
Summary
Showing Top 3 of 170
About Abivax S.A.
https://www.abivax.comABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2025 | $2.02M ▼ | $95.71M ▼ | $-100.78M ▼ | -5K% ▼ | $-1.59 ▼ | $-93.59M ▲ |
| Q4-2024 | $7.4M ▲ | $140.38M ▲ | $-94.6M ▼ | -1.28K% ▼ | $-1.5 ▼ | $-131.97M ▼ |
| Q2-2024 | $3.39M ▲ | $43.39M ▼ | $-40.82M ▲ | -1.2K% ▲ | $-0.65 ▲ | $-39.91M ▲ |
| Q4-2023 | $2.33M ▲ | $92.08M ▲ | $-95.79M ▼ | -4.12K% ▼ | $-1.98 ▼ | $-92.08M ▼ |
| Q2-2023 | $2.25M | $39.21M | $-51.95M | -2.31K% | $-1.45 | $-39.21M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2025 | $60.95M ▼ | $119.64M ▼ | $167.92M ▲ | $-48.28M ▼ |
| Q4-2024 | $144.22M ▼ | $205.23M ▼ | $164.64M ▲ | $40.58M ▼ |
| Q2-2024 | $222.32M ▼ | $284.49M ▼ | $158.02M ▲ | $126.47M ▼ |
| Q4-2023 | $260.99M ▲ | $327.06M ▲ | $131.05M ▲ | $196.01M ▲ |
| Q2-2023 | $114.38M | $171.08M | $90.59M | $80.49M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $-100.78M ▼ | $-66.62M ▲ | $1.27M ▲ | $-8.77M ▲ | $60.95M ▲ | $-66.68M ▲ |
| Q4-2024 | $-94.6M ▼ | $-68.9M ▼ | $1.15M ▼ | $-12.12M ▼ | $0 | $-69.3M ▼ |
| Q2-2024 | $-40.82M ▲ | $-42.59M ▲ | $13.46M ▲ | $40.32M ▼ | $0 ▼ | $-42.71M ▲ |
| Q4-2023 | $-95.79M ▼ | $-71.16M ▼ | $-8.78M ▼ | $222.58M ▲ | $137.56M ▲ | $-71.28M ▼ |
| Q2-2023 | $-51.95M | $-27.6M | $-1.71M | $117.99M | $87.44M | $-29M |
CEO
Marc de Garidel
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 19
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Guggenheim
Buy
BTIG
Buy
Citizens
Market Outperform
JMP Securities
Market Outperform
Citizens Capital Markets
Market Outperform
LifeSci Capital
Outperform
Grade Summary
Showing Top 6 of 8
Price Target
Institutional Ownership
TCG CROSSOVER MANAGEMENT, LLC
Shares:7.11M
Value:$889.02M
UBS GROUP AG
Shares:4.46M
Value:$557.7M
DARWIN GLOBAL MANAGEMENT, LTD.
Shares:3.16M
Value:$395.59M
Summary
Showing Top 3 of 170